Top

Diabetologia

Published in:

01-06-2004 | Article

Interleukin-6 and tumor necrosis factor-α are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness

Authors: A. L. Carey, C. R. Bruce, M. Sacchetti, M. J. Anderson, D. B. Olsen, B. Saltin, J. A. Hawley, M. A. Febbraio

Published in: Diabetologia | Issue 6/2004

Abstract

Aims/hypothesis

Our aim was to examine the possible direct relationship of interleukin-6 and TNFα with insulin sensitivity in humans.

Methods

We carried out two series of euglycaemic-hyperinsulinaemic clamp experiments. In the first (CLAMP1), skeletal muscle mRNA expression and plasma concentrations of IL-6 and TNFα were examined in patients with Type 2 diabetes (n=6), subjects matched for age (n=6), and young healthy (n=11) control subjects during a 120-min supra-physiological hyperinsulinaemic (40 mU·m⁻²·min⁻¹) euglycaemic clamp. In the second series of experiments (CLAMP2), patients with Type 2 diabetes (n=6) and subjects matched for age (n=7) were studied during a 240-min high-physiological hyperinsulinaemic (7 mU·m⁻²·min⁻¹) euglycaemic clamp, during which arterial and venous (femoral and subclavian) blood samples were measured for IL-6 and TNFα flux.

Results

In both experiments the glucose infusion rate in the patients was markedly lower than that in the other groups. In CLAMP1, basal skeletal muscle IL-6 and TNFα mRNA were the same in all groups. They were not affected by insulin and they were not related to the glucose infusion rate. In CLAMP2, neither cytokine was released from the arm or leg during insulin stimulation in either group. In both experiments plasma concentrations of these cytokines were similar in the patients and in the control subjects, although in CLAMP1 the young healthy control group had lower (p<0.05) plasma IL-6 concentrations. Using data from all subjects, a strong positive correlation (r=0.85; p<0.00001) was observed between basal plasma IL-6 and BMI. Conversely, a negative relationship (r=−0.345; p<0.05) was found between basal plasma TNFα and BMI, although this was not significant when corrected for BMI. When corrected for BMI, no relationship was observed between either basal plasma IL-6 or TNFα and GIR.

Conclusions/interpretation

These data show that the increased circulating IL-6 concentrations seen in patients with Type 2 diabetes are strongly related to fat mass and not insulin responsiveness, and suggest that neither IL-6 nor TNFα are indicative of insulin resistance.

Bastard JP, Jardel C, Bruckert E et al. (2000) Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85:3338–3342

Bastard JP, Maachi M, Van Nhieu JT et al. (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87:2084–2089CrossRefPubMed

Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745–E751PubMed

Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA (1996) The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest 97:1111–1116PubMed

Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610–614PubMed

Fernandez-Real JM, Broch M, Vendrell J et al. (2000) Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49:517–520

Pickup JC, Mattock MB, Chusney GD, Burt D (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286–1292CrossRefPubMed

Lyngso D, Simonsen L, Bulow J (2002) Interleukin-6 production in human subcutaneous abdominal adipose tissue: the effect of exercise. J Physiol 543:373–378CrossRefPubMed

Steensberg A, Fischer CP, Sacchetti M et al. (2003) Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol 548:631–638CrossRefPubMed

10.

Wallenius V, Wallenius K, Ahren B et al. (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75–79CrossRefPubMed

11.

Mohamed-Ali V, Goodrick S, Rawesh A et al. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196–4200PubMed

12.

Febbraio MA, Pedersen BK (2002) Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 16:1335–1347CrossRefPubMed

13.

Keller C, Steensberg A, Pilegaard H et al. (2001) Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J 15:2748–2750PubMed

14.

Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Pedersen BK (2000) Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529:237–242PubMed

15.

Carey AL, Lamont B, Andrikopoulos S, Koukoulas I, Proietto J, Febbraio MA (2003) Interleukin-6 gene expression is increased in insulin-resistant rat skeletal muscle following insulin stimulation. Biochem Biophys Res Commun 302:837–840CrossRefPubMed

16.

Steensberg A, Febbraio MA, Osada T et al. (2001) Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. J Physiol 537:633–639PubMed

17.

Winkler G, Lakatos P, Salamon F et al. (1999) Elevated serum TNF-alpha level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients. Diabet Med 16:207–211

18.

Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG (1999) Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 84:272–278PubMed

19.

Pfeiffer A, Janott J, Mohlig M et al. (1997) Circulating tumor necrosis factor alpha is elevated in male but not in female patients with type II diabetes mellitus. Horm Metab Res 29:111–114PubMed

20.

Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87–91PubMed

21.

Stephens JM, Pekala PH (1992) Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. Regulations is coordinate and independent of protein synthesis. J Biol Chem 267:13580–13584PubMed

22.

Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM (1994) Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 91:4854–4858PubMed

23.

Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665–668PubMed

24.

Stephens JM, Lee J, Pilch PF (1997) Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 272:971–976CrossRefPubMed

25.

Nolte LA, Hansen PA, Chen MM, Schluter JM, Gulve EA, Holloszy JO (1998) Short-term exposure to tumor necrosis factor-alpha does not affect insulin-stimulated glucose uptake in skeletal muscle. Diabetes 47:721–726PubMed

26.

Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R (1996) Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881–885

27.

DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab 237:E214–E223

28.

Febbraio MA, Steensberg A, Fischer CP, Keller C, Hiscock N, Pedersen BK (2002) IL-6 activates HSP72 gene expression in human skeletal muscle. Biochem Biophys Res Commun 296:1264–1266CrossRefPubMed

29.

Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Pedersen BK (2002) IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab 283:E1272–E1278PubMed

30.

Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9:414–417PubMed

31.

Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–3399

32.

Stouthard JM, Romijn JA, van der Poll T et al. (1995) Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol Endocrinol Metab 268:E813–E819

33.

Birkenkamp KU, Esselink MT, Kruijer W, Vellenga E (2000) An inhibitor of PI3-K differentially affects proliferation and IL-6 protein secretion in normal and leukemic myeloid cells depending on the stage of differentiation. Exp Hematol 28:1239–1249CrossRefPubMed

34.

Krogh-Madsen R, Plomgaard P, Keller P, Keller C, Pedersen BK (2004) Insulin stimulates interleukin-6 and tumor necrosis factor-{alpha} gene expression in human subcutaneous adipose tissue. Am J Physiol Endocrinol Metab 286:E234–E238CrossRefPubMed

35.

Febbraio MA, Keenan J, Angus DJ, Campbell SE, Garnham AP (2000) Preexercise carbohydrate ingestion, glucose kinetics, and muscle glycogen use: effect of the glycemic index. J Appl Physiol 89:1845–1851

36.

Febbraio MA, Steensberg A, Starkie RL, McConell GK, Kingwell BA (2003) Contracting skeletal muscle releases IL-6, but not TNF-α, in healthy subjects and patients with type 2 diabetes. Metabolism 52:939–954CrossRefPubMed

37.

Bluher M, Kratzsch J, Paschke R (2001) Plasma levels of tumor necrosis factor-alpha, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care 24:328–334PubMed

38.

Paolisso G, Rizzo MR, Mazziotti G et al. (1998) Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 275:E294–E299

39.

Winkler G, Salamon F, Salamon D, Speer G, Simon K, Cseh K (1998) Elevated serum tumour necrosis factor-alpha levels can contribute to the insulin resistance in Type II (non-insulin-dependent) diabetes and in obesity. Diabetologia 41:860–861

40.

Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK (2003) Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 17:884–886PubMed

41.

Dietze D, Koenen M, Rohrig K, Horikoshi H, Hauner H, Eckel J (2002) Impairment of insulin signaling in human skeletal muscle cells by co-culture with human adipocytes. Diabetes 51:2369–2376

42.

Miyazaki Y, Glass L, Triplitt C, Wajcberg E, Mandarino LJ, DeFronzo RA (2002) Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 283:E1135–E1143PubMed

43.

Hotamisligil GS (2000) Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord [Suppl 4] 24:S23–S27

Title: Interleukin-6 and tumor necrosis factor-α are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness
Authors: A. L. Carey
C. R. Bruce
M. Sacchetti
M. J. Anderson
D. B. Olsen
B. Saltin
J. A. Hawley
M. A. Febbraio
Publication date: 01-06-2004
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 6/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-004-1403-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Interleukin-6 and tumor necrosis factor-α are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 6/2004

Peroxisome proliferator-activated receptor γ gene polymorphisms and restenosis in diabetic patients after stenting in coronary arteries

Early vitamin E supplementation attenuates diabetes-associated vascular dysfunction and the rise in protein kinase C-β in mesenteric artery and ameliorates wall stiffness in femoral artery of Wistar rats

Enhanced insulin secretion and cholesterol metabolism in congenic strains of the spontaneously diabetic (Type 2) Goto Kakizaki rat are controlled by independent genetic loci in rat chromosome 8

Nerve growth factor promotes reparative angiogenesis and inhibits endothelial apoptosis in cutaneous wounds of Type 1 diabetic mice

BABYDIET, a feasibility study to prevent the appearance of islet autoantibodies in relatives of patients with Type 1 diabetes by delaying exposure to gluten

Large-scale studies of the HphI insulin gene variable-number-of-tandem-repeats polymorphism in relation to Type 2 diabetes mellitus and insulin release

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page